N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation

Objective. To explore the effects of N1-methylnicotinamide (MNAM) on insulin resistance and glucose metabolism in obese type 2 diabetes mellitus (T2DM) mice and regulatory mechanisms of the NAD-dependent deacetylase sirtuin-1 (SIRT1)/forkhead box protein O1 (FOXO1) pathway. Methods. Blood glucose an...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingfan Zhang, Yu Chen, Cong Liu, Ling Li, Ping Li
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2020/1080152
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850107028124467200
author Jingfan Zhang
Yu Chen
Cong Liu
Ling Li
Ping Li
author_facet Jingfan Zhang
Yu Chen
Cong Liu
Ling Li
Ping Li
author_sort Jingfan Zhang
collection DOAJ
description Objective. To explore the effects of N1-methylnicotinamide (MNAM) on insulin resistance and glucose metabolism in obese type 2 diabetes mellitus (T2DM) mice and regulatory mechanisms of the NAD-dependent deacetylase sirtuin-1 (SIRT1)/forkhead box protein O1 (FOXO1) pathway. Methods. Blood glucose and insulin levels were examined in mice. HE and oil red O staining were used to observe the effects of MNAM on liver lipid deposition in ob/ob mice. Real-time PCR and Western blotting were used to detect expression of gluconeogenesis, insulin signaling-related proteins, and SIRT1/FOXO1 pathway-related proteins. L-O2 cells were cultured as a model of insulin resistance, and MNAM and SIRT1 inhibitors were administered in vivo. Residual glucose and insulin signaling-related proteins were detected and the mechanisms associated with the SIRT1/FOXO1 signaling pathway in insulin resistance explored. Results. MNAM can effectively reduce levels of fasting blood glucose and insulin, improve liver morphology, and reduce lipid accumulation in obese type 2 diabetes mellitus mice. MNAM also downregulates the key proteins in the gluconeogenesis pathway in the liver, upregulates Sirt1 expression, and reduces acetylation of the FOXO1 protein. In vitro, MNAM could promote the glucose uptake capacity of L-O2 cells induced by palmitic acid (PA), a saturated fatty acid that induces IR in various scenarios, including hepatocytes, improving insulin resistance. As Sirt1 expression was inhibited, the reduction of hepatocyte gluconeogenesis and the regulation of the insulin signaling pathway by MNAM were reversed. Conclusion. MNAM activates SIRT1 and inhibits acetylation of FOXO1, which in turn regulates insulin sensitivity in type 2 diabetic mice, leading to a reduction of hepatic glucose output and improvement of insulin resistance.
format Article
id doaj-art-4bcedcc8a25e408f971c495676ec497a
institution OA Journals
issn 2314-6745
2314-6753
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-4bcedcc8a25e408f971c495676ec497a2025-08-20T02:38:41ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/10801521080152N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 AcetylationJingfan Zhang0Yu Chen1Cong Liu2Ling Li3Ping Li4Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, ChinaDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, ChinaDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, ChinaDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, ChinaDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, ChinaObjective. To explore the effects of N1-methylnicotinamide (MNAM) on insulin resistance and glucose metabolism in obese type 2 diabetes mellitus (T2DM) mice and regulatory mechanisms of the NAD-dependent deacetylase sirtuin-1 (SIRT1)/forkhead box protein O1 (FOXO1) pathway. Methods. Blood glucose and insulin levels were examined in mice. HE and oil red O staining were used to observe the effects of MNAM on liver lipid deposition in ob/ob mice. Real-time PCR and Western blotting were used to detect expression of gluconeogenesis, insulin signaling-related proteins, and SIRT1/FOXO1 pathway-related proteins. L-O2 cells were cultured as a model of insulin resistance, and MNAM and SIRT1 inhibitors were administered in vivo. Residual glucose and insulin signaling-related proteins were detected and the mechanisms associated with the SIRT1/FOXO1 signaling pathway in insulin resistance explored. Results. MNAM can effectively reduce levels of fasting blood glucose and insulin, improve liver morphology, and reduce lipid accumulation in obese type 2 diabetes mellitus mice. MNAM also downregulates the key proteins in the gluconeogenesis pathway in the liver, upregulates Sirt1 expression, and reduces acetylation of the FOXO1 protein. In vitro, MNAM could promote the glucose uptake capacity of L-O2 cells induced by palmitic acid (PA), a saturated fatty acid that induces IR in various scenarios, including hepatocytes, improving insulin resistance. As Sirt1 expression was inhibited, the reduction of hepatocyte gluconeogenesis and the regulation of the insulin signaling pathway by MNAM were reversed. Conclusion. MNAM activates SIRT1 and inhibits acetylation of FOXO1, which in turn regulates insulin sensitivity in type 2 diabetic mice, leading to a reduction of hepatic glucose output and improvement of insulin resistance.http://dx.doi.org/10.1155/2020/1080152
spellingShingle Jingfan Zhang
Yu Chen
Cong Liu
Ling Li
Ping Li
N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
Journal of Diabetes Research
title N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
title_full N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
title_fullStr N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
title_full_unstemmed N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
title_short N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation
title_sort n1 methylnicotinamide improves hepatic insulin sensitivity via activation of sirt1 and inhibition of foxo1 acetylation
url http://dx.doi.org/10.1155/2020/1080152
work_keys_str_mv AT jingfanzhang n1methylnicotinamideimproveshepaticinsulinsensitivityviaactivationofsirt1andinhibitionoffoxo1acetylation
AT yuchen n1methylnicotinamideimproveshepaticinsulinsensitivityviaactivationofsirt1andinhibitionoffoxo1acetylation
AT congliu n1methylnicotinamideimproveshepaticinsulinsensitivityviaactivationofsirt1andinhibitionoffoxo1acetylation
AT lingli n1methylnicotinamideimproveshepaticinsulinsensitivityviaactivationofsirt1andinhibitionoffoxo1acetylation
AT pingli n1methylnicotinamideimproveshepaticinsulinsensitivityviaactivationofsirt1andinhibitionoffoxo1acetylation